03:21 , Nov 17, 2018 |  BioCentury  |  Product Development

Betting Combos on Biomarkers

Despite lackluster monotherapy data at SITC from the latest tranche of immunotherapy candidates, drug developers are moving into combination trials with PD-1 and PD-L1 inhibitors based on biomarkers of pharmacodynamic activity. Results from the next...
18:50 , Nov 16, 2018 |  BC Week In Review  |  Company News

Google Brings Geisinger CEO on Board to Focus on Healthcare

Beyond a quick mention of Verily Life Sciences LLC and AI, Google Inc. is saying little about what it plans to do with its healthcare initiatives now that David Feinberg is leaving Geisinger Health System...
17:28 , Nov 16, 2018 |  BC Week In Review  |  Clinical News

Innovent starts Phase III of PD-1 inhibitor in squamous NSCLC after Phase Ib readout

Innovent Biologics Inc. (HKSE:1801) reported data from 17 evaluable patients with squamous non-small cell lung cancer (NSCLC) in cohort E of an open-label, Chinese Phase Ib trial showing that anti-PD-1 mAb sintilimab (IBI308) plus gemcitabine...
15:57 , Nov 16, 2018 |  BC Week In Review  |  Financial News

CStone lines up for Hong Kong IPO

With an anti-PD-L1 mAb in Phase III testing and cornerstone investors such as WuXi Ventures and Boyu Capital, immuno-oncology company CStone Pharmaceuticals Co. Ltd. (Suzhou, China) proposed to list on the Hong Kong stock exchange...
22:55 , Nov 15, 2018 |  BC Innovations  |  Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
23:43 , Nov 12, 2018 |  BC Extra  |  Financial News

CStone lines up for Hong Kong IPO

With an anti-PD-L1 mAb in Phase III testing and cornerstone investors such as WuXi Ventures and Boyu Capital, immuno-oncology company CStone Pharmaceuticals Co. Ltd. (Suzhou, China) on Monday proposed to list on the Hong Kong...
00:39 , Nov 10, 2018 |  BC Extra  |  Company News

Google brings Geisinger CEO on board to focus on healthcare

Beyond a quick mention of Verily Life Sciences LLC and AI, Google Inc. is saying little about what it plans to do with its healthcare initiatives now that David Feinberg is leaving Geisinger Health System...
18:20 , Nov 9, 2018 |  BC Week In Review  |  Company News

Oblato gains rights to glioblastoma compound OKN-007

Oblato Inc. exercised its 2016 option to receive all rights to glioblastoma compound OKN-007 from Oklahoma Medical Research Foundation (Oklahoma City, Okla.). Oblato is a subsidiary of GtreeBNT Co. Ltd. (Seongnam, South Korea). The foundation...
04:47 , Nov 9, 2018 |  BC Innovations  |  Tools & Techniques

HitGen’s DNA for small molecules

With more than 60 partnerships under its belt, HitGen Ltd. has become a major gateway for companies to access DNA-encoded library technology -- a high efficiency form of combinatorial chemistry that upstages high throughput screening....
23:28 , Nov 2, 2018 |  BioCentury  |  Finance

Bye-bye, build-to-buy

As another Inception Sciences Inc. company secures an exit, Versant Ventures plans to move away from its build-to-buy model to focus on creating stand-alone companies with broader portfolios and investor syndicates. On Oct. 31, Ophthotech...